Orally Disintegrating Tablet Market Forecast Reveals Where Future Industry Value Will Be Created
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Orally Disintegrating Tablet Market Size Outlook: How Fast Will Revenue Grow Through 2030?
The market for orally disintegrating tablets has experienced robust expansion over the last few years. Valued at $16.2 billion in 2025, it is projected to reach $17.62 billion by 2026, reflecting a compound annual growth rate (CAGR) of 8.8%. Several factors drove growth during the historic period, including restricted knowledge about orally disintegrating tablets, the continued predominance of conventional tablets, insufficient focus on pediatric and geriatric populations, a strong dependency on hospital pharmacy channels, and a hesitant uptake of specialized drug formulations.
The market for orally disintegrating tablets is set to experience notable expansion over the coming years. Projections indicate it will reach $24.43 billion by 2030, with a compound annual growth rate (CAGR) of 8.5%. This anticipated growth during the forecast period is driven by several factors, including advances in ODT formulation technologies, a growing preference among patients for treatments that offer convenience and better compliance, the expansion of both online and retail pharmacy networks, the increasing prevalence of central nervous system and gastrointestinal disorders, and heightened research and development efforts focused on antipsychotic and antiepileptic medications. Key trends shaping this period encompass a rising demand for dosage forms that are easy to swallow and more patient-friendly, a broader targeting of pediatric and geriatric populations, the growth of hospital and retail pharmacy distribution channels, a heightened emphasis on therapies with rapid onset of action, and the greater incorporation of specialized drug classes into ODT formulations.
Download A Free Sample Report For Comprehensive Market Insights:
Orally Disintegrating Tablet Market Expansion Drivers: What Is Shaping Future Growth?
The growing prevalence of neurological conditions is anticipated to drive the expansion of the orally disintegrating tablet market in the coming years. These disorders are medical issues that impact the nervous system, encompassing the brain and peripheral nerves, thereby impairing its regular function. The rise in such cases is largely attributable to increased life expectancy, as age-related ailments like Alzheimer’s and Parkinson’s become more frequent, leading to a higher overall count of patients. Orally disintegrating tablets assist in managing neurological disorders by facilitating simpler and quicker drug delivery, which is particularly beneficial for individuals suffering from dysphagia or cognitive deficits, thereby boosting medication compliance, guaranteeing consistent dosing, and augmenting therapeutic outcomes. For example, in March 2023, data from the Alzheimer’s Association, a US-based nonprofit volunteer health organization, indicated that around 6.7 million Americans aged 65 and over were living with Alzheimer’s dementia in 2023, with forecasts pointing to a rise to 13.8 million by 2060. So, the mounting frequency of neurological disorders is accelerating progress in the orally disintegrating tablet market.
Orally Disintegrating Tablet Market Segment Breakdown: Which Categories Generate The Most Revenue?
The orally disintegrating tablet market covered in this report is segmented –
1) By Drug Class: Anti-Psychotics, Anti-Epileptics, Central Nervous System Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensives, Non-Steroidal Anti-Inflammatory Drugs, Anti-Allergy Drugs, Proton Pump Inhibitors, Other Drug Classes
2) By Disease Indication: Central Nervous System Disease, Gastrointestinal Disease, Cardiovascular System Disorders, Allergy, Other Disease Indications
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Drug Stores
4) By Consumer Type: Pediatric, Adult, Geriatric
Subsegments:
1) By Anti-Psychotics: Atypical Anti-Psychotics, Typical Anti-Psychotics
2) By Anti-Epileptics: Sodium Channel Blockers, GABA Analogs, Other Anti-Epileptics
3) By Central Nervous System Stimulants: Amphetamine Derivatives, Methylphenidate, Other CNS Stimulants
4) By Anxiolytics: Benzodiazepines, Non-Benzodiazepine Anxiolytics
5) By Anti-Parkinsonian Drugs: Dopamine Agonists, MAO-B Inhibitors, Other Anti-Parkinsonian Drugs
6) By Anti-Hypertensives: Beta-Blockers, Calcium Channel Blockers, ACE Inhibitors, Other Anti-Hypertensives
7) By Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen, Diclofenac, Other NSAIDs
8) By Anti-Allergy Drugs: Antihistamines, Corticosteroids
9) By Proton Pump Inhibitors: Omeprazole, Esomeprazole
10) By Other Drug Classes: Antiemetics, Antimigraine Drugs, Other Therapeutic Classes
Orally Disintegrating Tablet Market Strategic Trends: What Is Defining The Next Phase Of Growth?
Major players within the orally disintegrating tablet sector are prioritizing drug formulation breakthroughs, especially patient-focused delivery systems, to boost treatment compliance and achieve superior health results. A patient-centric delivery approach involves designing medications that are simpler and more convenient to take, thereby enhancing the overall therapeutic experience and adherence. As an example, in May 2025, the US healthcare company Viatris Inc. rolled out Gen-Clozapine orally disintegrating tablets (ODT) across Canada, delivering a fresh therapeutic choice for individuals battling treatment-resistant schizophrenia. This product brings several distinctive attributes that mark a notable advancement in managing this condition within the country. Being the first clozapine ODT available on the Canadian market, it offers a user-friendly option that dissolves rapidly in the mouth without requiring water, which benefits patients who face swallowing difficulties or struggle with consistent medication use. The tablets come in multiple strengths—12.5 mg, 25 mg, 50 mg, 100 mg, and 200 mg—enabling flexible and accurate dose adjustments tailored to each person’s requirements. By incorporating clozapine, the sole antipsychotic sanctioned for treatment-resistant schizophrenia, this ODT formulation ensures compatibility with well-established care protocols.
Orally Disintegrating Tablet Market Key Players And Strategic Industry Positioning
Major companies operating in the orally disintegrating tablet market are Pfizer Inc., Merck & Co Inc., Bayer AG, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma USA Inc., Dr. Reddy’s Laboratories Limited, Cadila Healthcare Limited, Torrent Pharmaceuticals Limited, Adare Pharma Solutions.
Access The Complete Orally Disintegrating Tablet Market Report:
Orally Disintegrating Tablet Market Regional Analysis And Leading Geography
North America was the largest region in the orally disintegrating tablet market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the orally disintegrating tablet market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
